We scan new podcasts and send you the top 5 insights daily.
Tom says he sees no big role for adjuvant immune therapy because waiting for neoadjuvant chemotherapy and cystectomy means many patients never reach that phase. He prefers early immune therapy, as in Niagara, because some patients are cured with neoadjuvant treatment. This sequencing argument favors perioperative IO over postoperative-only IO.
The success of neoadjuvant immunotherapy trials like Niagara and those with EV-Pembro means most patients will receive immune therapy before surgery. This fundamentally shifts the clinical landscape, making the question of starting adjuvant immunotherapy less relevant as perioperative treatment becomes the standard.
While neoadjuvant-only immunotherapy has a strong rationale, a patient-level cross-trial comparison of CheckMate 816 (neoadjuvant) and 770T (perioperative) suggests the addition of adjuvant therapy improves event-free survival, favoring a full perioperative approach.
Standard cancer surgery often removes lymph nodes—the factories producing immune cells. Administering immunotherapy *before* this destructive process is critical. It arms the immune system while it is still intact and capable of mounting a powerful, targeted response against the tumor.
The traditional CRC treatment path (chemo-surgery-chemo) is being upended. New data shows giving immunotherapy before surgery can be so effective that the surgery itself becomes the "adjuvant" or follow-up treatment, representing a major paradigm shift.
Unlike chemotherapy, neoadjuvant immunotherapy appears more effective than adjuvant therapy because it leverages the in-situ tumor and its associated lymph nodes as a 'training ground.' This allows the immune system to generate a robust, specific anti-tumor response before the primary tumor and nodal basin are surgically removed.
Clinical trial data suggests immunotherapy's timing is crucial in early-stage TNBC. Given with chemotherapy before surgery (neoadjuvant), it improves outcomes. However, when given alone after surgery (adjuvant), the IMPASSION 030 trial showed no benefit and was halted for futility, indicating pre-surgical tumor priming is essential.
Giving EV Pembro perioperatively for muscle-invasive bladder cancer provides the best chance for a cure. Waiting to use it in the first-line metastatic setting is a major gamble, as many patients relapse and may not get a second chance at effective therapy. The consensus is to use the best treatment upfront.
Dr. Radvanyi advocates for a paradigm shift: treating almost all cancers with neoadjuvant immunotherapy immediately after diagnosis. This "kickstarts" an immune response before standard treatments like surgery and chemotherapy, which are known to be immunosuppressive, can weaken the patient's natural defenses against the tumor.
In curative settings like early-stage bladder cancer, the strategy of "saving" a powerful treatment like a PD-1 inhibitor is logically unsound. If the disease biology allows progression despite the treatment now, it's unlikely to respond better later. The only valid reason to withhold the best upfront option is toxicity, not a misguided attempt at sequencing.
Testing antibody-drug conjugate (ADC) and immunotherapy combinations in the neoadjuvant setting is strategically superior because an intact tumor's antigen load enhances T-cell priming and immunotherapy efficacy, an advantage lost in the post-surgery adjuvant setting.